TSE:2802Food
What Ajinomoto (TSE:2802)'s ADC Technology Licensing Deal With Astellas Means For Shareholders
In late October 2025, Astellas Pharma announced it has signed a licensing agreement with Ajinomoto Co., Inc. to utilize Ajinomoto's AJICAP antibody-drug conjugate (ADC) technology in its contract development and manufacturing operations for biopharmaceuticals.
This partnership underscores Ajinomoto's expanding capabilities in the biopharma sector, as it leverages its proprietary technology to support the development of innovative next-generation treatments for patients.
We'll examine how...